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Abstract
CD8+ T cells recognize and eliminate tumors in an antigen-specific manner. Despite progress in 
characterizing the antitumor T cell repertoire and function, identifying their target antigens 
remains a challenge. Here, we describe the use of chimeric receptors called Signaling and 
Antigen-presenting Bifunctional Receptors (SABRs) in a novel cell-based platform for T Cell 
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Receptor (TCR) antigen discovery. SABRs present an extracellular peptide-MHC complex and 
induce intracellular signaling via a TCR-like signal upon binding with a cognate TCR. We devised 
a strategy for antigen discovery using SABR libraries to screen thousands of antigenic epitopes. 
We validated this platform by identifying the targets recognized by public TCRs of known 
specificities. Moreover, we extended this approach for personalized neoantigen discovery. The 
antigen discovery platform reported here will provide a scalable and versatile way to develop 
novel targets for immunotherapy.
Introduction:
The ability of CD8+ T cells to recognize and kill cancer cells is well-established1 and 
exploited by immunotherapies such as vaccines2, checkpoint blockade3,4, and adoptive T 
cell therapies5. A CD8+ T cell encodes a unique surface T Cell Receptor (TCR) that 
recognizes 8-12 residue long peptide epitopes presented on class I Major Histocompatibility 
Complex (MHC) molecules, also known as Human Leukocyte Antigens (HLA) in humans6. 
When a TCR complex binds cognate peptide-MHC (pMHC), the associated CD247 (CD3ζ) 
chains dimerize to initiate downstream signaling. Multiple signaling cascades are activated, 
leading to rapid gene expression driven by the transcription factors NF-κB, AP-1, and 
NFAT7. In CD8+ T cells, TCR signaling induces expression of early activation markers 
(CD69 and LAMP1), release of cytotoxic granules, and secretion of cytokines, ultimately 
killing the target cell7. The interaction of cognate TCR and pMHC complexes generates a 
high degree of specificity towards a target antigen. T cells can recognize epitopes presented 
by tumor cells and infiltrate the tumor microenvironment. Antitumor T cells respond to two 
kinds of tumor-derived epitopes: 1) Public or private epitopes originating from non-mutated, 
tissue specific antigens or cancer-testis antigens; and 2) Private neoantigens originating from 
non-synonymous mutations8. Both endogenous antigens and neoantigens can be used to 
provide targets of immunotherapies.
Considerable progress has been made towards understanding the T cell repertoire9 and 
function10 using high throughput genomics, transcriptomics, and proteomics. However, one 
of the bottlenecks in the field of tumor immunology is the identification of the antigen 
recognized by a particular antitumor CD8+ T cell. Several techniques have been developed 
to identify cognate antigens for T cells. The most common approach uses pMHC multimers 
to identify antigen-specific T cells by flow cytometry11,12. Antigen discovery using pMHC 
multimers requires ab initio knowledge of the antigenic landscape, is not scalable beyond 
103 antigens, but can identify multiple antigenic specificities simultaneously. This approach 
has been used to discover public tumor antigens13 as well as private neoantigens12,14. A 
recently reported approach uses yeast display of epitope libraries for antigen discovery15. 
However, this approach is technically challenging because of the requirement of soluble 
TCR, does not represent the physiological TCR-pMHC interaction, but is antigen-agnostic 
and scalable to 106-108 epitopes16. These limitations underscore the need for new 
techniques for T cell antigen discovery.
Here, we sought to develop novel antigen discovery techniques to address the unmet need. In 
two parallel studies (Li et al, accompanying manuscript), we present cell-based platforms for 
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T cell antigen discovery. We describe chimeric receptors called Signaling and Antigen-
presenting Bifunctional Receptors (SABRs) that allow identification of a successful TCR-
pMHC interaction. We report a strategy for TCR antigen discovery using SABR libraries 
and demonstrate its use for known public TCRs and a private neoantigens-specific TCR. 
Through these studies, we describe a flexible and scalable method for T cell antigen 
discovery.
Results:
Signaling and Antigen-presenting Bifunctional Receptors (SABRs)
T cell activation upon recognizing a target antigen induces detectable gene expression. 
However, as MHC molecules lack signaling domains, detection of recognized Antigen 
Presenting Cells (APCs) is challenging. To address this, we constructed chimeric receptors 
called Signaling and Antigen-presenting Bifunctional Receptors (SABRs). The extracellular 
domain of a SABR is a covalently linked peptide-β2microglobulin-MHC trimer17, fused to 
an intracellular CD3ζ signaling domain with a CD28 co-stimulatory domain. We 
constructed two variations of SABRs, SABR-F and SABR-E, which contained the entire 
MHC molecule or only the extracellular part of the MHC molecule respectively 
(Supplementary Fig 1a). We hypothesized that upon interaction with a TCR, SABRs 
presenting its cognate antigen will induce an intracellular signal (Fig 1a). To detect the 
signal induced by SABRs, we used NFAT-GFP-Jurkat cells, which express GFP upon 
receiving a signal via CD3ζ. We transduced NFAT-GFP-Jurkat cells with SABRs presenting 
the EAAGIGILTV epitope (from the MART1/MLANA protein) on HLA-A*0201 (hereafter 
known as A2-MART1-SABR) or the KRWIILGLNK epitope (KK10, from the HIV-1 gag 
protein) from HIV-1 on HLA-B*2705 (hereafter known as B27-KK10-SABR). We co-
incubated transduced NFAT-GFP-Jurkat cells with Jurkat cells expressing TCRs and 
measured GFP expression by flow cytometry after 8 hours. Specifically, we used F5 
(recognizes A2-MART118), EC27 (recognizes B27-KK1019), SL9 (recognizes A2-
SLYNTVATL20) TCRs or untransduced Jurkat cells. GFP expression was detected only in 
co-culture assays with the cognate TCR-SABR-F pairs (Fig 1b and Supplementary Fig 1b). 
The SABR-F construct showed higher signal than SABR-E, and therefore, was used for 
further experiments (Supplementary Fig 1c). SABR signaling was titratable and sensitive 
enough to detect at least as low as 10 F5+ Jurkat cells mixed with 10,000 untransduced 
Jurkat cells (Fig 1c). SABR signaling was rapid, as GFP signal was detectable within 3 
hours of co-incubation, and reached saturation within 6-8 hours (Fig 1d and Supplementary 
Fig 2). Both the sensitivity and kinetics were conserved for four different TCRs, EC27, 
FC4.3, FC5.5, and CP7.9, all of which recognize B27-KK1019. To test if SABR signaling 
can be induced upon recognition of low-affinity TCR-pMHC interactions, we used M1, an 
A2-MART1-specific TCR. The affinity of M1 TCR was too low to be measured by Surface 
Plasmon Resonance (SPR) as described previously21. F5 and M1 TCRs were 
indistinguishable in their ability to induce GFP signaling in NFAT-GFP-Jurkat cells 
expressing A2-MART1-SABR (Supplementary Fig 3). Taken together, these results show 
that SABRs can induce signaling upon successful and specific TCR-pMHC interaction, 
allowing identification of recognized APCs.
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SABRs allow different modes of antigen presentation
The endogenous MHC complexes present epitopes from newly translated proteins or 
endocytosed proteins via cross-presentation. To test if SABRs can also utilize these 
pathways for antigen presentation, we constructed an ‘empty’ version of SABRs that linked 
β2-microglobulin with HLA-A2 or B27, but did not genetically encode for an epitope 
(Supplementary Fig 4a). We incubated NFAT-GFP-Jurkat cells expressing the empty SABRs 
with soluble MART1 or KK10 peptides, and co-cultured them with Jurkat cells expressing 
F5 or EC27 TCRs. Both A2 and B27 empty SABRs induced a signal only in presence of the 
soluble peptide corresponding to the TCRs. Moreover, the signal induced by correct peptide-
TCR combinations was comparable to the signal induced by the corresponding SABRs 
presenting covalently linked epitopes (Fig 2a). Next, we constructed pentameric tandem 
minigenes22 (TMGs) to express the KK10 epitope along with four irrelevant CMV-derived 
epitopes (Supplementary Fig 4a). We co-transduced NFAT-GFP-Jurkat cells with the empty 
B27-SABR and the KK10 TMG. Following co-incubation with EC27- or F5-expressing 
Jurkat cells, the empty SABRs were able to present the endogenously expressed epitopes 
and induce specific signaling (Fig 2b). However, the overall signal was lower than the 
corresponding empty SABRs pulsed with soluble peptide. These results show that SABRs 
can present non-covalently linked epitopes generated through endogenous antigen 
processing and presentation pathways.
SABRs initiate a bona fide TCR signal
SABRs use a CD3ζ-CD28 domain for intracellular signaling, similar to chimeric antigen 
receptors (CARs) and TCRs. Therefore, we asked whether the intracellular signaling ability 
of SABRs is comparable to TCRs. We first tested if SABRs induce early activation markers 
in NFAT-GFP-Jurkat cells. NFAT-GFP-Jurkat cells transduced with the B27-KK10-SABR 
expressed CD69 specifically upon co-culture with Jurkat cells transduced with CP4.3 TCR, 
implying that SABR signaling activates endogenous gene expression (Fig 3a). If SABRs 
induce a bona fide TCR signal, they should confer cytotoxic capabilities to primary T cells. 
We transduced activated primary T cells with A2-MART1-SABR and incubated them with 
CFSE-labeled target cells expressing F5 TCR. Transduced primary T cells lysed Jurkat cells 
or primary T cells expressing the F5 TCR specifically (Fig 3b and c). Next, we compared 
the antigen sensitivity of SABRs and TCRs. We transduced NFAT-GFP-Jurkat cells with 
either empty A2-SABR or F5 TCR, and used them as effectors. As targets, we used Jurkat 
cells transduced with A2-SABR or F5 TCR (Fig 3d). We co-cultured effectors and targets in 
presence of a range of concentrations of the MART1 peptide, and measured GFP expression. 
Antigen sensitivity was determined as the concentration of the peptide required for half-
maximal signaling. The antigen sensitivity of SABRs was 30-fold lower as compared to 
TCRs (Fig 3e). We also interrogated the correlation between functional avidity of TCR-
pMHC interactions and signaling induced by SABRs. We first measured functional avidity 
of EC27 TCR towards six variants of the KK10 peptide as described previously19. We 
measured the ability of the EC27 TCR to induce GFP expression upon co-culture with 
empty B27 SABRs pulsed with the variants of the KK10 peptide. We observed a correlation 
between functional avidity of TCR-pMHC interactions with SABR signaling. Importantly, 
approximately 180-fold reduction of functional avidity observed between R2T and R2Q 
Joglekar et al. Page 4
Nat Methods. Author manuscript; available in PMC 2019 September 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
variants was still able to induce detectable SABR signaling (Supplementary Fig 4b). Taken 
together, these results show that SABRs signal similar to TCRs, albeit with lower antigen 
sensitivity.
Proof-of-concept of using SABR libraries for antigen discovery
Next, we asked if SABR libraries presenting a large number of epitopes can be used to 
screen successful TCR-pMHC interactions. We designed a strategy to construct and use 
SABR libraries for T cell antigen discovery of ‘orphan’ TCRs with unknown antigens. First, 
a list of target epitopes was generated to encode for 12,055 peptides (A2-SABR-library) 
consisting of all known HLA-A*0201-restricted epitopes from the Immune Epitope 
Database23 (Supplementary Table 3). The protein sequences of the target epitopes were 
backtranslated to generate codon-optimized oligonucleotide sequences along with 15bp 
overhangs that overlap with the SABR vector. The entire list of oligonucleotides for the 
library was synthesized using pooled synthesis. The pooled library was then amplified and 
cloned using ligation-free cloning into the SABR vector plasmid. (Supplementary Fig 5 and 
Supplementary Fig 6a). The SABR libraries were packaged into lentiviral vectors and used 
to transduce NFAT-GFP-Jurkat cells. We first interrogated if the A2-SABR-library allows 
identification of the cognate antigen for F5 and SL9 TCRs. We transduced NFAT-GFP-
Jurkat cells with the A2-SABR-library, and incubated them with Jurkat cells expressing the 
TCRs. After 10 hours of co-culture, we sorted GFP+CD69+ cells by FACS (Supplementary 
Fig 6b and Fig 4a) and extracted genomic DNA from them. The epitope portion of the 
SABRs was amplified and sequenced (Supplementary Fig 6c). The sequencing reads were 
aligned with the SABR vector backbone using Burrows-Wheeler alignment24. Aligned reads 
were translated to their protein sequences, and the number of reads corresponding to each 
epitope was counted and reported in a list. A minimum of three replicates of the co-
incubation assay were performed. For each replicate, a numerical rank was given to each 
epitope based on descending order of the number of reads. The rank from three replicates for 
each assays was averaged and reported as ‘Average Rank’ (Supplementary Fig 6c). First, we 
plotted the average ranks of each of the epitopes from the SL9 sort against those from F5 
sort (Fig 4b). The top six epitopes in the F5 sort were analogs of EAAGIGILTV, indicating 
successful identification of its antigen (Fig 4c). Six out of the top ten epitopes from the SL9 
sort were analogs of SLYNTAVATL (Fig 4d). The average fold-enrichment of the top hits 
from the F5- and SL9-sorts over the Mock-sort was 296 and 70 respectively. The noise 
observed in the SL9 sort is possibly due to the higher number of analogs of the 
SLYNTVATL peptide. We compared the ranks of all the analogs of EAAGIGILTV and 
SLYNTVATL in the sorts. Six out of twenty-two EAAGIGILTV analogs were identified in 
the F5 sort (Supplementary Fig 7a), whereas nine out of sixty SLYNTVATL analogs were 
identified in the SL9 sort (Supplementary Fig 7b). The lack of identification of all the 
analogs is presumably due to reduced cross-reactivity of the F5 or SL9 TCRs towards them. 
Indeed, analogs SLYNTIATL (V6I) and SLFNTVATL (Y3F) are documented escape 
mutations in the SLYNTVATL epitope25,26. We validated the top six hits from the F5 sort by 
in vitro cytotoxicity assays. We observed that all six analogs of the Mart1 peptide were 
specifically recognized by the F5 TCR, leading to induction of cytotoxicity (Fig 4e). 
Nevertheless, these experiments showed that a SABR library approach could identify the 
cognate antigen of a TCR by screening thousands of epitopes.
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Personalized neoantigen discovery using SABRs
To further demonstrate the versatility of SABR libraries, we used a personalized approach 
for neoantigen discovery. A recent study identified a neoantigen-specific, tumor-reactive 
TCR from a melanoma patient using DNA-barcoded tetramers. The identified TCR 
(neoTCR) recognizes a non-synonymous mutation in the USP7 protein (S.Peng, 
J.M.Zaretsky, A.H.C.Ng, W.Chour, M.T.Bethune, A.Hsu, E.Holman, X.Ding, K.Guo, J.Kim, 
A.M.Xu, J.E.Heath, W.Noh, J.Zhou, Y.Su, Y.Lu, J.Mclaughlin, D.Cheng, O.N.Witte, 
D.Baltimore, A.Ribas and J.R.Heath, unpublished data). We generated a SABR library 
presenting 3,251 predicted HLA-A*0201-restricted epitopes (NeoAg-SABR library) 
corresponding to 108 non-synonymous mutations found in the tumor (Supplementary Table 
4). We used the neoTCR as a surrogate for a tumor-reactive orphan TCR and used the 
NeoAg-SABR library to identify its antigen. We co-cultured Jurkat cells transduced with 
neoTCR and NFAT-GFP-Jurkat cells expressing the NeoAg-SABR library, sorted GFP
+CD69+ cells, then sequenced and ranked epitopes from the sorted cells (Fig 5a). For each 
epitope, we plotted the average ranks from neoTCR sort against mock-sort (Fig 5b). The top 
seven hits in the neoTCR sort were epitopes derived from USP7, demonstrating successful 
identification of the neoantigen using our approach (Fig 5c). The non-synonymous D798Y 
mutation in USP7 was predicted to generate thirty overlapping neoepitopes, out of which we 
identified seven as cognate epitopes of neoTCR (Supplementary Fig 8). To validate the 
seven detected epitopes, we constructed individual SABRs to present them. NFAT-GFP-
Jurkat cells transduced with these SABRs induced GFP expression upon co-culture with 
Jurkat cells expressing neoTCR (Fig 5d). Unexpectedly, the SABR presenting the unmutated 
DLYHRVDVIF epitope also induced signaling upon recognition by neoTCR. Primary T 
cells transduced with neoTCR were able to specifically kill target cells pulsed with the 
peptides corresponding to seven detected neoepitopes, but not cells pulsed with the 
unmutated peptide (Fig 5e). We posit that by covalently linking the unmutated epitope, we 
may enforce its binding to MHC, unlike peptide pulsing. While this may lead to a false 
identification of the unmutated peptide as a ‘hit’, we expect subsequent validation by 
orthogonal assays to erase this concern. These results demonstrate validation as well as 
successful personalization of the antigen discovery approach presented here.
Discussion:
In this study, we report a novel, cell-based technique for TCR antigen discovery. We 
invented chimeric receptors called SABRs that combine antigen presentation and signaling 
to allow identification of APCs recognized by a given TCR. Using SABR libraries 
presenting thousands of epitopes, we showed unbiased identification of the targets of known 
melanoma- and HIV-specific TCRs. Moreover, we adapted this strategy for personalized 
neoantigen discovery. We envision employing the SABR library approach for antigen 
discovery of antitumor CD8+ T cells (Supplementary Fig 6). The flexibility of this approach 
allows customizations required for antigen discovery for public or private TCRs. A SABR 
library based on shared tumor gene expression among patients can identify the antigen of a 
shared, public TCR, whereas, a SABR library based on a single patient’s tumor mutanome 
can interrogate the specificity of a private TCR. While we have shown data for HLA-
A*0201 and HLA-B*2705, SABRs can presumably be constructed for any class I HLA. 
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Further testing and optimization may be required to expand the use of SABRs to all HLA-A, 
B, and C alleles from a patient. Furthermore, this approach can be used for antigen discovery 
for pathogen-reactive or self-reactive TCRs. Finally, we posit that SABRs based on class II 
MHC alleles will be able to signal similarly, and therefore be used for antigen discovery of 
TCRs from CD4+ T cells. This will greatly aid antigen discovery of autoimmune CD4+ T 
cells and regulatory T cells27,28. Beyond antigen discovery, SABRs can also be purposed for 
different applications. SABR libraries incorporating variants of a single epitope may be used 
to interrogate TCR crossreactivity and to identify altered peptide ligands or heteroclitic 
peptides29. The signaling ability of SABRs may also be used to impart functional attributes 
to primary T cells for therapeutic use. For instance, arming primary T cells with SABRs may 
allow them to eliminate autoreactive T cells via fratricide, or to suppress autoreactive T cells 
by inducing a tolerogenic signal30.
Our approach presents several advantages over the current TCR antigen discovery 
techniques. The scale offered by SABRs, currently up to 106 epitopes, is considerably higher 
than a multimer or a functional screen approach31,32. SABR libraries do not rely on 
synthesis of peptides or MHC molecules, and are therefore far easier to construct, and unlike 
yeast display systems, do not require production of soluble TCRs15, which is technically 
challenging and non-robust. Moreover, antigen discovery via yeast display requires several 
rounds of selection, outgrowth, and sequencing, whereas SABR libraries allow antigen 
discovery in a single, short-duration assay. Finally, SABR libraries do not require any 
specialized reagents, and can be employed by any standard immunology laboratory with 
access to facilities for molecular cloning, cell culture, FACS, and high-throughput 
sequencing.
There are also some technical limitations of using SABR libraries. Unlike yeast display 
systems that can present up to 106-108 epitopes15, SABRs are limited to 106 epitopes 
without requiring specialized cell culture facilities. Due to this limitation, the optimal use of 
SABRs will still require ab initio knowledge of antigenic epitopes. In their current form, 
SABRs allow antigen discovery for a single TCR in one assay, unlike multimers. In the 
future, this throughput may be increased by performing the screen on primary T cell samples 
directly, by multiplexing sequencing samples, or by multiplexing SABR libraries. However, 
if primary T cells were to be used for screening, cytotoxicity induced by the primary T cells 
towards SABR-expressing cells needs to be mitigated for optimization of this approach. We 
are currently developing this technique for multiplexed neoantigen discovery at a higher 
scale. At the current scale, the SABR library screens described here did not yield false 
positive hits for F5 and NeoAg TCRs, but did yield false positive hits identified in the SL9 
sort. This indicates that further optimization may be required to reduce false discovery rate 
and to improve signal:noise ratio in the case of atypical situations such as the SL9 TCR. 
Using more sensitive and specific techniques, such as single cell sorting and sequencing, the 
signal:noise ratio is expected to improve.
Collectively, we demonstrate that SABR libraries are versatile and powerful tools for antigen 
discovery. The simplicity and scalability of SABRs will greatly aid the development of novel 
antigen-guided immunotherapies.
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Online Methods:
Detailed step-by-step protocol
A detailed step-by-step protocol for SABR library generation and screening can be found in 
Supplementary Protocol. The same protocol can be found at Protocol Exchange (DOI: 
10.1038/protex.2018.126).
Reagents and oligonucleotide primers
The specific reagents used in the methods are detailed in Supplementary Table 1. The 
oligonucleotide primers used for cloning and sequencing are listed in Supplementary Table 
2. The lists of epitopes in the A2-SABR and the NeoAg-SABR libraries are in 
Supplementary Tables 3 and 4.
Cell lines and peptides
Jurkat cells and K562 cells (ATCC) were cultured in R10 (RPMI1640 (Corning) 
supplemented with 10% fetal bovine serum (Corning) and Penicillin/Streptomycin 
(Corning)). NFAT-GFP-Jurkat cells were a kind gift from Arthur Weiss and Yvonne Chen, 
and were cultured in R10 supplemented with 2 mg/ml G-418 (Corning). GXR-B27+ cells 
were a gift from Bruce D. Walker and were cultured in R10. Primary T cells were obtained 
from the CFAR virology core at University of California, Los Angeles, activated in R10 
supplemented with Immunocult CD3/28 (StemCell Technologies) and 40 U/ml IL-2 
(Miltenyi Biotec). HEK-293T cells (ATCC) were cultured in D10 (DMEM (Corning) 
supplemented with 10% fetal bovine serum (Corning) and Penicillin/Streptomycin 
(Corning)). All indicated peptides were synthesized by Pierce Thermo Fisher.
Construction of SABRs
Single molecules encoding for β2-microglobulin and HLA were synthesized as gBlocks 
(IDT) and amplified using primers SS-Fwd and CD28-Overlap-HLA-Rev. CD3ζ/CD28 
signaling domains were cloned from the J3 CAR (A gift from Pin Wang) using primers 
CD28Intracell-Fwd and XhoI-CD3z-Rev. The two parts of SABRs were assembled via PCR 
or via InFusion HD cloning kit (Takara). A synthetic 2kb fragment of non-specific stuffer 
DNA (IDT) flanked by BsmBI sites was cloned in place of the epitope. To clone a given 
epitope into a SABR vector, the vector was first linearized by BsmBI digestion (NEB) and 
gel purified using Nucleospin Gel and PCR kit (Takara). A single stranded oligonucleotide 
containing overlaps with the vector and the epitope was synthesized (IDT). The 
oligonucleotides were amplified using KOD polymerase (Milipore) and Oligo-Insert-Fwd 
and Oligo-Insert-Rev. Amplified oligonucleotide was cloned into the linearized SABR 
vector using InFusion HD cloning kit (Takara). All cloning reactions were transformed into 
Stellar competent cells (Takara), grown on LB+Agar plates containing 100 μg/ml 
Carbenicillin (Life Technologies), and individual colonies were inoculated in liquid culture. 
Plasmid minipreps were performed using Zyppy Miniprep kit (Zymo). Plasmids were 
verified by Sanger sequencing (Laragen).
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Cloning TCRs
Sequences for the F518, SL920, and neoTCR (S.Peng, J.M.Zaretsky, A.H.C.Ng, W.Chour, 
M.T.Bethune, A.Hsu, E.Holman, X.Ding, K.Guo, J.Kim, A.M.Xu, J.E.Heath, W.Noh, 
J.Zhou, Y.Su, Y.Lu, J.Mclaughlin, D.Cheng, O.N.Witte, D.Baltimore, A.Ribas and 
J.R.Heath, unpublished data) were synthesized as gBlocks (IDT) and cloned in the pCCLc-
MND-X backbone (a kind gift from Donald B. Kohn) along with a truncated form of 
LNGFR gene as described previously19. EC27, FC5.5, FC4.3, and CP7.9 TCRs were cloned 
as described previously19.
Generation and cloning of SABR libraries
To generate lists of epitopes to be clone into SABR vectors, two approaches were taken. In 
the universal A2-SABR library, all HLA-A*0201-restricted epitopes from Immune Epitope 
Database23 (IEDB) were downloaded. In the neoantigen SABR library, HLA-A*0201-
restricted neoepitopes generated from the tumor mutanome data reported previously 
(S.Peng, J.M.Zaretsky, A.H.C.Ng, W.Chour, M.T.Bethune, A.Hsu, E.Holman, X.Ding, 
K.Guo, J.Kim, A.M.Xu, J.E.Heath, W.Noh, J.Zhou, Y.Su, Y.Lu, J.Mclaughlin, D.Cheng, 
O.N.Witte, D.Baltimore, A.Ribas and J.R.Heath, unpublished data) were used. Protein 
sequences were back-translated to nucleotide sequences using the most abundant codon for 
each amino acid based on the GenScript Codon Usage Frequency Table Tool (GenScript). 
Oligonucleotides encoding for the epitopes and containing overlaps with the SABR vector 
were synthesized in pooled single stranded oligonucleotide libraries (Twist Biosciences). 
Oligonucleotide libraries were amplified and cloned into the SABR vector as described 
previously. To ensure sufficient coverage, bacterial cells transformed with the cloning 
reaction were inoculated directly into 500 ml liquid cultures overnight. The plasmid DNA 
containing the libraries was prepared using Nucleobond Xtra Maxi Plus EF (Takara).
Lentiviral vector production and transduction
Lentiviral vectors to express SABRs or TCRs were packaged using previously described 
procedures19. Briefly, 5×106 HEK-293T cells were plated on poly-L-Lysine coated plates 
for 24 hours, followed by transfection of a mixture of the lentiviral shuttle plasmid, pMDG-
VSVG, and pCMV-RD8.9 (a kind gift from Donald B. Kohn) using TransIT-293 (Mirus Bio) 
and OPTI-MEM (Life Technologies). Viruses were filtered through 0.45 micron syringe 
filters (Milipore) and stored at −80°C until further use. To transduce Jurkat, NFAT-GFP-
Jurkat, or Primary T cells, 2-5×105 cells were plated in culture medium and mixed with an 
equal volume of thawed virus in 12-well plates for three days. For NFAT-GFP-Jurkat cells, 
G-418 was added to the transduction mixture 48 hours later.
Retroviral vector production and transduction
RD114-pseudotyped retroviruses encoding for the B27-KK10-specific TCRs were produced 
in HEK-293T cells by transient transfection of three plasmids – an MSCV-based shuttle 
plasmid (a gift from R.A. Morgan), pHIT60, and pRD114. HEK-293T cells were plated at 
5×106 cells per 10 cm plate (Corning / BD Falcon) in D10. The cells were transfected using 
TransIT-293 (Mirus Bio) using the manufacturer’s protocol with 7.5 μg of shuttle plasmid, 
7.5 μg of pHIT60, and 5 μg of pRD114. The cell free supernatant was harvested 72 hours 
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later and filtered through a 0.45 micron filter (EMD Millipore), aliquoted, and stored at 
−80 °C until further use. To transduce primary human T cells, PBMCs were first activated 
for 7 days as described previously. The cells were mixed with retroviral vector at 1×106 cells 
per well in 12-well non tissue culture treated plates coated with 10 μg/ml Retronectin 
(Takara Bio) and spinfected at 1111g for 1.5 hours at room temperature. The cells were 
incubated for 72 hours post-transduction and harvested for functional assays.
Co-culture assays
For co-culture assays to test SABR signaling, 1-5×104 transduced NFAT-GFP-Jurkat cells 
were incubated with equal number of transduced Jurkat cells on 96 well flat or round bottom 
plates for 8-10 hours. The cells were then acquired on MACSQuant (Miltenyi) or stained 
with anti-CD69-APC-Cy7 (Biolegend) and then acquired on MACSQuant (Miltenyi). For 
SABR library assays, 1.5×106 SABR library cells were incubated with 1.5×106Jurkat cells 
in each well of a 6 well plate. At 8-10 hours after co-culture, cells were harvested, stained 
with anti-CD69-APC-Cy7 (Biolegend), and sorted on a BD FACS SORP (Becton-
Dickinson). Cytotoxicity assays were performed using target cells labeled with CFSE 
(Biolegend) as described previously19. For empty SABR assays, transduced NFAT-GFP-
Jurkat cells were incubated with 100 μg/ml of soluble peptide for 2 hours at 37 °C. Equal 
numbers of transduced Jurkat cells were then added to the cells, followed by 8-10 hours of 
co-culture. Gating strategies for these assays is shown in supplementary Fig 9. Functional 
avidity assays were performed using KK10 variant peptides as described previously19.
High throughput sequencing and analysis
Genomic DNA was extracted from sorted cells immediately following sorting using 
PureLink genomic DNA extraction kit (Life Technologies). The SABR vectors were 
amplified using KOD polymerase (Milipore) and 10:1:10 mixture of primers TruSeq-Univ-
SCTfixed-F, TruSeq-Read2-SCTfixed-R, and Truseq-Adapter-Index respectively. For each 
sample, 5-10 reactions using 1-30 ng of genomic DNA were performed for 30-35 cycles. 
The reactions were pooled and purified using Nucleospin Gel and PCR purification kit 
(Takara). The purified PCR product was analyzed on Bioanalyzer (Agilent) and subjected to 
sequencing on HiSeq 2500 (Illumina). Unaligned reads generated by the sequencer were 
stored in FASTQ files. The reads were first aligned to the SABR vector using Burrows-
Wheeler Alignment with a mismatch penalty of 124. For each aligned read, the epitope was 
translated and counted. All epitopes were ranked according to the number of reads, and an 
average rank was calculated for each read. The average rank was then used for further 
analysis.
Statistical analysis
Flow cytometry plots were analyzed on FlowJo (Treestar). Statistical analyses and graphical 
representations were generated by Microsoft Excel (Microsoft) and GraphPad Prism 
(Graphpad).
Joglekar et al. Page 10
Nat Methods. Author manuscript; available in PMC 2019 September 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Data availability
The data that support the findings of this study are available from the corresponding author 
upon request. The raw data can be found in source data file. The list of epitopes in the SABR 
libraries can be found in supplementary tables 3 and 4. The plasmids for HLA-A*0201-
SABR backbone (pCCLc-MND-A0201-SABR-Backbone, ID 119050), HLA-B*2705-
SABR backbone (pCCLc-MND-B2705-SABR-Backbone, ID 119051), A2-Mart1-SABR 
(pCCLc-MND-A0201-Mart1-SABR, ID 119052), and B27-KK10-SABR (pCCLc-MND-
B2705-KK10-SABR, ID 119053) are available through Addgene Inc. The sequencing data 
are deposited in Sequence Read Archive (SRR8207921: amplicon sequencing of A2-SABR-
library co-incubated with F5 TCR, SRR8207922: amplicon sequencing of A2-SABR-library 
co-incubated with SL9 TCR, SRR8207923: amplicon sequencing of A2-SABR-library co-
incubated with No TCR, SRR8207924: amplicon sequencing of A2-NeoAg-library co-
incubated with Neo TCR, SRR8207925: amplicon sequencing of A2-NeoAg-library co-
incubated with No TCR). The code used to analyze sequences is deposited at GitHub 
(https://github.com/Baltimore-Lab/nat-methods-SABR-trogo). The data availability 
statement can be found in Life Sciences Reporting Summary.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig 1. Signaling and antigen-presenting bifunctional receptors.
a. Schematics demonstrating SABRs and TCR-pMHC specific signaling. SCT – Single 
Chain Trimer, Ag - Antigen. Dotted lines indicate Gly-Ser linkers. b. GFP expression by 
SABR transduced NFAT-GFP-Jurkat cells upon co-culture with TCR-transduced Jurkat 
cells. Line and error bars indicate mean±sd, n=3 biologically independent cell culture 
replicates. c. Titration of SABR signal by measuring frequency of GFP+ cells in co-culture 
assays at 8 hours after co-culture. For FC4.3, FC5.5, CP7.9, and EC27 TCRs, NFAT-GFP-
Jurkat cells transduced with B27-KK10-SABR were used. Dots indicate values from n=1 
experiment. d. Timecourse of GFP expression by SABR transduced NFAT-GFP-Jurkat cells 
co-cultured with TCR-transduced Jurkat cells. For FC4.3, FC5.5, CP7.9, and EC27 TCRs, 
NFAT-GFP-Jurkat cells transduced with B27-KK10-SABR were used. Line and error bars 
indicate mean±sd, n=3 biologically independent cell culture replicates, n=4 for A2-Mart1.
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Fig 2. Different modes of antigen presentation by SABRs.
a. GFP expression by NFAT-GFP-Jurkats transduced with empty SABRs pulsed with soluble 
MART1 or KK10 peptides and co-cultured with Jurkat cells transduced with F5 or EC27 
TCRs. Line and error bars indicate mean±sd, n=3 biologically independent cell culture 
replicates. b. GFP expression by NFAT-GFP-Jurkats co-transduced with empty B27-SABRs 
KK10-TMG or transduced with empty B27-SABR and pulsed with KK10 peptide, and co-
cultured with Jurkat cells transduced with F5 or EC27 TCRs. Dots indicate individual values 
from n=2 biologically independent cell culture replicates.
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Fig 3. SABRs induce a bona fide TCR signal.
a. Induction of CD69 expression in co-culture assays with indicated TCR-SABR 
combinations is shown. The panel on the left is a representative plot showing discrimination 
of NFAT-GFP-Jurkat cells and Jurkat cells based on LNGFR expression. The panel on the 
right shows histogram for CD69 expression in the indicated populations. The shown data are 
representative of n=2 biologically independent cell culture replicates. b. Cytotoxicity 
induced by SABR-expressing primary T cells against Jurkat cells. Line and error bars 
indicate mean±sd for n=8 biologically independent cell culture replicates. c. Cytotoxicity 
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induced by SABR-expressing primary T cells against autologous target cells. Line and error 
bars indicate mean±sd for n=4 biologically independent cell culture replicates. d. Schematic 
of the assay to measure antigen sensitivity of A2-SABR (left) and of F5-TCR (right). e. 
Antigen sensitivity of SABR and TCR signaling indicating GFP signal as a function of 
MART1 peptide. Dots and error bars indicate mean±sd for n=3 biologically independent cell 
culture replicates. The dotted horizontal line indicates half-maximal signal.
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Fig 4. Proof-of-concept of using SABR libraries for TCR antigen discovery.
a. Sorting A2-SABR library cells based on GFP and CD69 expression in co-culture assays. 
Representative flow cytometry plots from one out of three biologically independent cell 
culture replicates are shown. The rectangle in the top right corner of each flow plot shows 
the gate used for the sort. Frequency of cells in the sort gate is indicated as percentage. b. 
Average ranks from F5 and SL9 sorts. Each dot represents the average rank for a unique 
epitope. Purple dots indicate EAAGIGILTV analogs and red dots indicate SLYNTVATL 
analogs. c. Average ranks for the top 20 hits from the F5 sort. Epitopes with asterisks 
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indicate EAAGIGILTV analogs. d. Average ranks for the top 20 hits from the SL9 sort. 
Epitopes with asterisks indicate SLYNTVATL analogs. e. Validation of the top hits in the F5 
sort by cytotoxicity assays performed on K562 cells expressing HLA-A2.1 and pulsed with 
the indicated peptides. Line and error bars indicate means±s.d. for n=3 biologically 
independent cell culture replicates.
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Fig 5. Personalized neoantigen discovery using SABR libraries.
a. Sorting NeoAg-SABR library cells based on GFP and CD69 expression in co-culture 
assays. Representative flow cytometry plots from one out of three biologically independent 
cell culture replicates are shown. The rectangle in the top right corner of each flow plot 
shows the gate used for the sort. Frequency of cells in the sort gate is indicated as 
percentage. b. Average ranks from neoTCR and mock sorts. Each dot represents the average 
rank for a unique epitope. Green dots indicate USP7-derived epitopes. c. Average ranks for 
the top 20 hits from the neoTCR sort. Epitopes with asterisks indicate USP7-derived 
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epitopes. d. Validation of top hits identified in the NeoAg-SABR screen by measuring GFP 
expression in co-culture assays. Line and error bars represent mean±sd, n=4 biologically 
independent cell culture replicates, n=2 for RYLYHRVDV. e. Validation of the top hits in the 
Neo TCR sort by cytotoxicity assays performed on K562 cells expressing HLA-A2.1 and 
pulsed with the indicated peptides. Line and error bars indicate means±s.d. for n=3 
biologically independent cell culture replicates.
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